|
|
Article: Genmab's Humax-CD20 Starts Phase III Work With NHL Focus.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Two months after starting a pivotal trial of its B-cell therapy, Humax-CD20, in chronic lymphocytic leukemia, Genmab A/S initiated a second Phase III, this one in patients with follicular non-Hodgkin's lymphoma (NHL) who are refractory to rituximab.
Results from both trials are expected next year, leaving Genmab with two potential pathways for seeking regulatory approval. Marketing applications could be filed in both the U.S. and Europe in 2007, and "the product could be marketed sometime in 2008, if everything goes as planned," said Helle Husted, director of investor relations for the Copenhagen, Denmark-based firm.
The planned ...